810389 Shandong Boan Biotechnology Co., Ltd.
- 0.000
- 0.0000.00%
Shandong Boan Biotechnology Co., Ltd. News
Weekly IPO | Gaosi Healthcare's stock offering is underway, 360 Digital-S rose 22.7% during the week
Three new shares were submitted this week; Gaoshi Medical, the biggest player in ophthalmology and medical devices in China, is actively offering shares; Haoyuan Technology has been oversubscribed 47 times; and 360 Digital Department-S has been listed, with good overall performance.
Express News | Shandong Boan Biotechnology Co., Ltd. submitted a form to apply for Hong Kong stock IPO on the Hong Kong Stock Exchange, with UBS and Anxin International as co-sponsors.
Securities Regulatory Commission: Boan Biotech's overseas IPO application has received materials
The Zhitong Finance App learned that on April 20, the Securities Regulatory Commission announced the progress of Shandong Boan Biotechnology Co., Ltd.'s “Approval of Overseas Initial Public Offering of Shares (Including Various Types of Shares and Derivative Forms of Shares such as Common Shares and Preferred Shares)” of Shandong Boan Biotechnology Co., Ltd. The progress has now reached the stage of receiving materials.
The application for the listing of desidumab injection in China has been accepted, and the Boan biological product pipeline is advancing at an accelerated pace
In recent years, Boan Biotech has stepped up efforts to efficiently promote the global R&D strategy of biopharmaceuticals. Currently, the R&D process for several drug candidates in the company's innovative R&D pipeline is progressing intensively. The Zhitong Finance App learned that Luye Pharmaceutical (02186) announced on October 13 that the marketing license application for desulumab injection (LY06006 /BA6101) developed by its holding subsidiary Boan Biotech has been accepted by the Drug Evaluation Center of the China Drug Administration. This means that the company has made phased progress in another achievement. Following the bevacizumab injection Boyunol®, LY0600
No Data